



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

FaR-RMS

Rhabdomyosarcoma (RMS) is a rare sarcoma, with 59% of cases presenting in children and the rest occurring in adulthood. Usually a combination of chemotherapy, radiotherapy and surgery is needed in order to achieve success in patients. Chemotherapy is used in the majority of patients with a positive response rate of around 80-85%. Unfortunately, if RMS do relapse, they are generally very difficult to treat and have a 5 year overall survival of less than 20%. It is the goal of the FaR-RMS study to improve the treatment of RMS in affected patients. The University of Birmingham in the United Kingdom is responsible for the international implementation of the study (sponsor). In Switzerland, the Swiss Paediatric Oncology Group (SPOG) is responsible for the conduct of the study (sponsor representative).

The FaR-RMS study divides patients into groups according to criteria such as severity of the tumour, relapse status and metastasis status. The FaR-RMS study asks a total of 10 study questions to which patients are assigned, according to the group that they are in. The questions include a dose finding study for new combinations of medicines, questions concerning chemotherapy (both before and after surgery / radiotherapy), radiotherapy questions, and questions concerning chemotherapy design for patients with a relapse. There are a total of 11 medicines that are tested in the different scenarios. The FaR-RMS study is currently in preparation in Switzerland.

Contact details for the sponsor representative in Switzerland:

Partner Relations
SPOG Coordinating Center
Effingerstrasse 33
3008 Bern
Phone: +41 31 389 91 89